Abstract

This brief overview provides insight into the vital contributions of metals to our existence. Their deficiency can contribute to various diseases in the human body, and numerous enzymes depend on them for catalytic functions. Additionally, metals have been utilized in the development of drugs aimed at treating conditions such as cancer, arthritis, and ulcers.

Keywords

• metals, metal complexes, metal-containing drugs, metal-containing enzymes.

References

• Metal Ions in Biological Systems. In: Seiler HG, Sigel H, Sigel A, editors. 14:1982.
• Holm RH, Pierre Kennepohl P, Solomon EI. Structural and Functional Aspects of Metal Sites in Biology. Chem Rev. 1996;96(7):2239‒2314.
• Lippard SJ, Berg JM. Principles of Bioinorganic Chemistry. Mill Valley: University Science Books; 1994.
• Cowan JA. Inorganic Biochemistry/An introduction. New Jersey: Wiley-VCH Inc;1994.
• Tietz Textbook of Clinical Chemistry. 2nd ed. In: Carl A, Burtis CA, et al, editors. Saunders: Philadelphia; 1994.
• De Silva JJRF, Williams RJP. The Biological Chemistry of the Elements. Clarendon Press: Oxford; 1991.
• Weiss RB, Christian MC. New Cisplatin Analogues in development. A review. Drugs. 1993;46(3):360–377.
• Lebwohl D, Canetta R. Clinical Development of Platinum Complexes in Cancer Therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522–1534.
• O’Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its Analogues. In Cancer Principles and Practice of Oncology. 5th ed. In: DeVita VT, Hellman S, Rosenberg SA, editors. Lippincott-Raven: Philadelphia; 1997. 418–431 p.
• O’Dwyer PJ, Stevenson JP, Johnson SW. Clinical Status of Cisplatin, Carboplatin, and Other Platinum-based Antitumor Drugs. In Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. In: Lippert B editor. Wiley-VCH: New York; 1999. 31–72 p.
• Highley MS, Calvert AH. Clinical Experience with Cisplatin and Carboplatin. In: Kelland LR, Farrell NP, editors. Platinum-Based Drugs in Cancer Therapy. Cancer Drug Discovery and Development. New Jersey: Humana Press; 2000. 89–113 p.
• Macdonald JS, Astrow AB. Adjuvant Therapy of Colon Cancer. Semin Oncol. 2001;28(1):30–40.
• Pelley RJ. Oxaliplatin: a new agent for colorectal cancer. Curr Oncol Rep. 2001;3(2):147–155.
• Carr JL, Tingle MD, McKeage MJ. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol. 2002;50(1):9–15.
• Farrell N, Qu Y, Hacker MP. Cytotoxicity and Antitumor Activity of Bis(Platinum) Complexes. A Novel Class of Platinum Complexes Active in Cell Lines Resistant to Both Cisplatin and 1,2-Diaminocyclohexane Complexes. J Med Chem. 1990;33(8):2179–2184.
• Farrell N. DNA Binding and Chemistry of Dinuclear Platinum Complexes. Comm Inorg Chem. 1995;16(6):373–389.
• Farrell N. DNA Binding of Dinuclear Platinum Complexes. In Advances in DNA Sequence Specific Agents. In: Hurley LH, Chaires JB, editors. Bingley: JAI Press. 1996;2:187–216.
• Farrell N. Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin. Cancer Invest. 1993;11(5):578–589.
• Roat-Malone RM. Bioinorganic Chemistry: A Short Course. 2nd ed. New Jersey: John Wiley & Sons; 2007. 19–20 p.
• Keppler BK, Friesen C, Moritz, HG, et al. Tumor-inhibiting bis(β-Diketonato) metal complexes. Budotitane, cis-diethoxybis(1-phenylbutane-1,3-dionato)titanium(IV). Bioinorg Chem. 2005;78:97‒127.
• Kostova I. Ruthenium Complexes as Anticancer Agents. Curr Med Chem. 2006;13(9):1085–1107.
• Lentz F, Drescher A, Lindauer A, et al. Pharmacokinetics of a Novel Anticancer Ruthenium Complex (KP1019, FFC14A) in a Phase I Dose-Escalation Study. Anticancer Drugs. 2009;20(2):97–103.
• Sava G, Clerici K, Capozzi I, et al. Reduction of Lung metastasis by ImH[trans- RuCl4(DMSO)Im]: Mechanism of the Selective Action Investigated on Mouse Tumors. Anticancer Drugs. 1999;10(1):129–138.
• Bergamo A, Gagliardi R, Scarcia V, et al. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther. 1999;289(1):559–564.
• Zorzet S, Bergamo A, Cocchietto M, et al. Lack of in vitro Cytotoxicity, Associated to Increased G2-M Cell Fraction and Inhibition of Matrigel Invasion, May Predict In Vivo-Selective Antimetastasis Activity of Ruthenium Complexes. J Pharmacol Exp Ther. 2000;295(3):927–933.
• Hartinger CG, Jakupec MA, Zorbas-Seifried S, et al. KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chem Biodivers. 2008;5(10):2140–2155.
• Briand GG, Burford N. Bismuth Compounds and Preparations with Biological or Medicinal Relevance. Chem Rev. 1999;99(9):2601–2658.
• Reglinski J. Chemistry of Arsenic, Antimony, and Bismuth. In: Norman NC editor. London: Blackie Academic & Professional; 1998.
• Felson DT, Anderson JJ, Meenan RF. The Comparative Efficacy and Toxicity of Second-Line Drugs in Rheumatoid Arthritis Results of Two Meta-analyses. Arth Rheumat. 1999;33(10):1449–1461.
• Klinkhoff A. An Editorial is a Golden Opportunity. J Rheumat. 2005;32(6):978–979.
• Thomson AJ, Gray HB. Bio-inorganic Chemistry. Curr Opin Chem Biol. 1998;2(2):155–158.
• Waldron KJ, Robinson NJ. How do Bacterial Cells Ensure that Metalloproteins Get the Correct Metal? Nature Rev Microbiol. 2009;71(1):25–35.
• Glusker JP, Katz AK, Bock CW. Metal Ions in Biological Systems. Rigaku J. 1999;16(2):8‒16.
• Bock CW, Kaufman A, Glusker JP. Coordination of Water to Magnesium Cations. lnorg Chem. 1994;33(3):419‒427.
• Bock CW, Katz AK, Markham GD, et al. Manganese as a Replacement for Magnesium and Zinc: Functional Comparison of the Divalent Metal Ions. J Amer Chem Soc. 1999;121(32):7360‒7372.
• Katz AK, Glusker JP. Roles of Zinc and Magnesium Ions in Enzymes. Adv Mol Struct Res.1998;4:227‒279.
• Carrell HL, Glusker JP, Berger V. et al. X-ray Analysis of D-Xylose Isomerase at 1.9A: Native Enzyme in Complex with Substrate and with a Mechanism-designed Inactivator. Proc Natl Acad Sci USA. 1989:86(12):4440‒4444.
• Leung D, Abbenante G, Fairlie DP. Protease Inhibitors: Current Status and Future Prospects. J Med Chem. 2000;43(3):305‒341.
• Gupta SP. Quantitative Structure-Activity Relationship Studies on Zinc-Containing Metalloproteinase Inhibitors. Chem Rev. 2007;107(7):3042‒3087.
• Parkin G. Synthetic Analogues Relevant to the Structure and Function of Zinc Enzymes. Chem Rev. 2004;104(2):699‒768.
• Martin RB. Practical hardness scales for metal ion complexes. Inorg Chim Acta. 2002;339:27‒33.

This work is licensed under a Creative Commons Attribution 4.0 International License.